FDA Approves Moderna's First mRNA Flu Vaccine After Initial Refusal

The Food and Drug Administration has approved Moderna's messenger RNA (mRNA) flu vaccine, marking the first time an mRNA vaccine for influenza has received authorization.

This approval follows an initial refusal by the FDA to review the vaccine. The new vaccine utilizes mRNA technology, similar to that used in some COVID-19 vaccines, to prompt an immune response against influenza viruses. This development is seen as an advancement for public health, offering a new approach to flu prevention. The flu vaccine is intended to protect against influenza, a respiratory illness that can cause severe illness and death, particularly in older adults.

The mRNA technology aims to provide a more effective or faster-acting protection compared to traditional flu vaccines. Further details on the vaccine's performance and availability are expected as it moves towards wider distribution. The approval signifies a step forward in the application of mRNA technology beyond its initial use in combating the COVID-19 pandemic.